Bristol-Myers Squibb Co
featured
Cramer has become more cautious on the market right now and conditions are creating a "nightmare scenario" for just about everyone involved, he said on CNBC.
» Read More
More
-
Baxter International Inc. rose$. 15 or. 2 percent, to $70.88. Bristol-Myers Squibb Co. rose$. 41 or. 9 percent, to $46.85. Hospira rose$. 17 or. 5 percent, to $36.59.
-
Baxter International Inc. rose$. 06 or. 1 percent, to $70.79. Bristol-Myers Squibb Co. rose$. 51 or 1.1 percent, to $46.95. Hospira rose$. 02 or. 1 percent, to $36.44.
-
Some scientists to move to Cambridge before 2016. LONDON, June 18- Turning around drugmaker AstraZeneca will be a long haul, with a strategy of revamping research and boosting acquisitions set to take up to four years to pay off, its chief executive said on Tuesday.
-
Baxter International Inc. rose$. 11 or. 2 percent, to $70.84. Bristol-Myers Squibb Co. rose$. 28 or. 6 percent, to $46.72. Hospira rose$. 10 or. 3 percent, to $36.52.
-
Baxter International Inc. rose$. 13 or. 2 percent, to $70.73. Bristol-Myers Squibb Co. fell$. 36 or. 8 percent, to $46.44. Hospira rose$. 18 or. 5 percent, to $36.42.
-
Baxter International Inc. rose$. 09 or. 1 percent, to $70.69. Bristol-Myers Squibb Co. fell$. 13 or. 3 percent, to $46.67. Hospira rose$. 28 or. 8 percent, to $36.52.
-
Baxter International Inc. rose$. 39 or. 6 percent, to $70.99. Bristol-Myers Squibb Co. rose$. 14 or. 3 percent, to $46.95. Hospira rose$. 36 or 1.0 percent, to $36.60.
-
Baxter International Inc. fell$. 15 or. 2 percent, to $70.60. Bristol-Myers Squibb Co. fell$. 37 or. 8 percent, to $46.80. Hospira fell$. 22 or. 6 percent, to $36.24.
-
Baxter International Inc. rose$. 08 or. 1 percent, to $70.83. Bristol-Myers Squibb Co. fell$. 23 or. 5 percent, to $46.94. Hospira fell$. 12 or. 3 percent, to $36.34.
-
Baxter International Inc. rose$. 35 or. 5 percent, to $71.10. Bristol-Myers Squibb Co. rose$. 19 or. 4 percent, to $47.36. Hospira fell$. 09 or. 2 percent, to $36.37.
-
Baxter International Inc. rose $1.00 or 1.4 percent, to $70.75. Bristol-Myers Squibb Co. rose$. 60 or 1.3 percent, to $47.17. Hospira rose $1.21 or 3.4 percent, to $36.46.
-
Baxter International Inc. rose$. 61 or. 9 percent, to $70.36. Bristol-Myers Squibb Co. rose$. 41 or. 9 percent, to $46.98. Hospira rose$. 39 or 1.1 percent, to $35.63.
-
Baxter International Inc. fell$. 01 or percent, to $69.74. Bristol-Myers Squibb Co. fell$. 09 or. 2 percent, to $46.48. Hospira fell$. 05 or. 1 percent, to $35.20.
-
Baxter International Inc. fell$. 02 or percent, to $69.75. Bristol-Myers Squibb Co. fell$. 72 or 1.5 percent, to $46.57. Hospira fell$. 83 or 2.3 percent, to $35.25.
-
Baxter International Inc. rose$. 15 or. 2 percent, to $69.92. Bristol-Myers Squibb Co. fell$. 17 or. 4 percent, to $47.12. Hospira fell$. 61 or 1.7 percent, to $35.47.
-
Baxter International Inc. rose$. 27 or. 4 percent, to $70.04. Bristol-Myers Squibb Co. rose$. 25 or. 5 percent, to $47.54. Hospira fell$. 33 or. 9 percent, to $35.75.
-
Baxter International Inc. fell$. 47 or. 7 percent, to $69.77. Bristol-Myers Squibb Co. fell$. 02 or percent, to $47.29. Hospira fell$. 31 or. 9 percent, to $36.08.
-
Baxter International Inc. fell$. 28 or. 4 percent, to $69.96. Bristol-Myers Squibb Co. rose$. 00 or percent, to $47.31. Hospira fell$. 15 or. 4 percent, to $36.24.
-
Baxter International Inc. fell$. 56 or. 8 percent, to $69.68. Bristol-Myers Squibb Co. fell$. 45 or. 9 percent, to $46.87. Hospira fell$. 63 or 1.7 percent, to $35.76.
-
Baxter International Inc. rose$. 27 or. 4 percent, to $70.24. Bristol-Myers Squibb Co. fell$. 19 or. 4 percent, to $47.31. Hospira rose$. 56 or 1.6 percent, to $36.39.
Most Popular Video
An airline passenger records a Chinese cargo handler as he tosses boxes of something on to and off of a conveyor belt for shipment. Hopefully, the cargo was packed well.
Tuesday, 18 Jun 2013 | 9:33 AM ETPlans to take PC maker Dell private by leveraging the company's balance sheet are misguided, CNBC's Jim Cramer said on "Squawk on the Street" Tuesday, because the company is facing lower margins and an increased competition from rival Hewlett Packard.
Tuesday, 18 Jun 2013 | 12:47 PM ETSupply shortages and rising rates are positive for the real estate market, Colony Capital CEO Tom Barrack says.